Dynavax Technologies has been granted a patent for CpG-adjuvanted SARS-CoV-2 vaccines. The patent describes the composition and methods of producing and administering the vaccines, which include an inactivated SARS-CoV-2 whole virus particle, a CpG-containing oligodeoxynucleotide, and an alum adjuvant. The vaccines are designed to induce neutralizing antibodies against SARS-CoV-2 without causing antibody-dependent enhancement of the disease. GlobalData’s report on Dynavax Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dynavax Technologies, personalized cancer vaccines was a key innovation area identified from patents. Dynavax Technologies's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Cpg-adjuvanted sars-cov-2 vaccine with neutralizing antibodies
A recently granted patent (Publication Number: US11684669B2) describes a composition for immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic. The composition includes an inactivated SARS-CoV-2 whole virus particle, a CpG-containing oligodeoxynucleotide (CpG-ODN), and an alum adjuvant. The immunogenic composition is designed to induce the production of neutralizing antibodies against SARS-CoV-2 when administered intramuscularly. Importantly, the composition does not induce antibody-dependent enhancement of SARS-CoV-2-associated disease.
The inactivated SARS-CoV-2 whole virus particle in the composition has an S protein with at least 96% amino acid sequence identity to a specific sequence (SEQ ID NO: 3). The alum adjuvant used is aluminum hydroxide. The ratio of alum to CpG-ODN in the composition ranges from about 1:3 to about 3:1, with a preferred ratio of about 1:2. The alum content in the composition is between about 0.8 to about 1.2 mg/mL, with a preferred content of about 1 mg/mL. The CpG-ODN content ranges from about 1.5 to about 2.5 mg/mL, with a preferred content of about 2 mg/mL.
The composition also includes additional SARS-CoV-2 particles that have RNA sequences corresponding to specific DNA sequences. These additional particles have at least 90%, 95%, or 99% sequence identity to the specified DNA sequences. The patent also describes a kit that includes the SARS-CoV-2 immunogenic composition along with a second immunogenic composition, which can be another SARS-CoV-2 virus immunogenic composition or a composition for immunization against other viruses such as Japanese encephalitis, Zika, Dengue, influenza, or Chikungunya.
The patent also discloses a method for producing the SARS-CoV-2 immunogenic composition. The method involves producing SARS-CoV-2 whole virus particles with an S protein that has at least 96% amino acid sequence identity to a specific sequence (SEQ ID NO: 3). The particles are then inactivated and incorporated into the immunogenic composition along with the CpG-ODN and alum adjuvant.
Overall, this patent describes a specific composition and method for immunization against SARS-CoV-2, the virus responsible for COVID-19. The composition includes inactivated virus particles, a CpG-ODN, and an alum adjuvant, and is designed to induce the production of neutralizing antibodies without causing antibody-dependent enhancement of disease. The patent also discloses additional SARS-CoV-2 particles and a kit that includes the immunogenic composition along with other virus immunogenic compositions.
To know more about GlobalData’s detailed insights on Dynavax Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
